Global, Multi-Center, Repeat-Dose, Phase 2 Study of RZ358 (Ersodetug), an Insulin Receptor Antibody, for Congenital Hyperinsulinism We are pleased to share the findings from our global, multi-center Phase 2b study (RIZE) evaluating RZ358 (ersodetug) in patients with congenital hyperinsulinism (cHI) in a detailed paper published today in Med by Cell Press. The study demonstrated that ersodetug was generally safe, well-tolerated, and led to clinically meaningful improvements in glycemic control, particularly at higher dose levels. These results support the potential of ersodetug as a targeted therapy for cHI, addressing a significant unmet medical need. For detailed insights, read the full paper: https://bit.ly/4hGNyzS. #WeAreRezolute #RareDiseases #CongenitalHyperinsulinism #Hypoglycemia #ClinicalTrial
Rezolute, Inc.
生物技术研究
Redwood City，California 9,138 位关注者
Rezolute is developing transformative therapeutics for rare and metabolic diseases.
关于我们
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). For more information, visit: www.rezolutebio.com.
- 网站
-
https://www.rezolutebio.com
Rezolute, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Redwood City，California
- 类型
- 上市公司
地点
-
主要
获取路线
275 Shoreline Dr.
Ste. 500
US，California，Redwood City，94065
Rezolute, Inc.员工
动态
-
We're #hiring a new Senior Manager /Associate Director Clinical Supply Chain in Redwood City, California. Apply today or share this post with your network.
-
Are you ready to take your career to the next level? Rezolute is seeking passionate professionals to help us advance solutions for rare diseases. Learn about our opportunities: https://lnkd.in/gn9nRV4M. #WeAreRezolute #CareersInHealthcare #JoinOurMission
-
Spending #RareDiseaseDay2025 with colleagues in Lisbon taking part in the Congenital Hyperinsulinism International‘s Collaborative Research Network meeting. #RezoluteCaresAboutRare
-
-
It's #RareDiseaseDay2025! Learn more: https://rarediseaseday.org. Rezolute is advancing innovative treatments to help improve the lives of people living with congenital and tumor hyperinsulinism. #WeAreRezolute #RareDisease
-
-
It is Rare Disease week!
The path from research to reality is filled with challenges, from policy uncertainty, funding gaps, and regulatory hurdles. Companies like Rezolute are driving solutions forward. Rezolute, Inc. is a leader among small rare disease companies fighting for real progress this #RareDiseaseWeek and beyond.
-
-
Rezolute is committed to equipping healthcare providers with the tools and treatments needed to address hyperinsulinism effectively. Explore our clinical trials and innovative solutions at rezolutebio.com. #WeAreRezolute #RareDisease #HealthcareLeadership
-
-
We're #hiring a new Director Medical Affairs in Redwood City, California. Apply today or share this post with your network.
-
We're #hiring a new Associate Director Patient Affairs in Redwood City, California. Apply today or share this post with your network.
-
Rezolute is advancing its mission to develop transformative therapies for hyperinsulinism (HI) and rare diseases: https://bit.ly/40YFC72. ?? The FDA has granted Breakthrough Therapy?& Orphan Drug Designations?to ersodetug, recognizing its potential impact in treating congenital HI and tumor HI. ?? Our Phase 3 sunRIZE study?continues to progress, with infant enrollment now approved?after a successful safety review by the Data Monitoring Committee (DMC). ?? Backed by $105.3M in cash and investments, we are well-positioned to execute our clinical programs and drive innovation in rare disease treatment. #WeAreRezolute #Hyperinsulinism #ClinicalTrials #RareDisease